Overall verdict
Buy
7.0/10
1-year performance
+8.29%
Score breakdown
Up 8.3% over 1 year, 55% of the 52-week range.
Strongest: Financial strength 10.0/10. Weakest: Growth 2.0/10.
12 analysts, target +0.3% vs the price.
Bradsaúde S.A. provides private dental care plans in Brazil. The company operates through Corporate, Small and Medium-Sized Enterprise (SME), Individual, and Other segments. The company manages and sells dental care plans to corporations and/or individuals.
It is also involved in commercial advisory, consulting, and business management services ; develops and licenses software programs ; wholesale and retail trade of products and equipment, sanitizers, drugs, medicines, pharmaceutical inputs, and related items ; provision of storage, loading, organization, tidying, custody of goods, technical, and administrative programming services, as well as general management of assets and business.
In addition, the company engages in integrating technologies to develop dental solutions; and provide specialized services related to accidents and illnesses, besides actuarial, financial, administrative, and commercial and risk management services. The company was formerly known as Odontoprev S.A. and changed its name to Bradsaúde S.A. in April 2026. Bradsaúde S.A. was founded in 1987 and is headquartered in Barueri, Brazil. Bradsaúde S.A. operates as a subsidiary of Bradesco Saúde S.A.
Sector
Health Care
Industry
Health Care Providers and Services
Primary listing
Bmfbovespa
Brazil
CEO
Mr. Carlos Alberto Iwata Marinelli
Founded
1987
Employees
1 957
Revenue / employee
1.2M BRL
Next earnings
October 21, 2026
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
16.57 BRL
52-week low
10.39 BRL
1-year performance
8.29%
Rising
Year-to-date performance
24.78%
Rising
Drawdown
-16.72%
Marked drawdown
Position in the 52-week range
55% of range
Range: 13.10 BRL - 19.60 BRL (2 methods agree)
The price implies growth of 19.24% per year; the company grows at 11.56%.
Gross margin 15.6%, net margin 10.6%, ROIC 10.4%, ROE 10.5%.
Net margin
10.60%
Exceptional
Sector 0.88%|S&P 12.97%
Gross margin
15.62%
Low
Return on equity (ROE)
10.54%
Fair
Sector 9.02%|S&P 16.52%
Return on invested capital (ROIC)
10.44%
Exceptional
Free cash flow margin (FCF)
6.65%
Exceptional
Profit-to-cash conversion (FCF conversion)
0.63x
Low
Margin stability
1.8 pts
Very steady
Revenue to net income
Growth
2.0/10Revenue up 1213.1% over 1 year, 6.5% a year over 5, EPS 11.6% a year over 5.
Revenue (trailing 12 months)
10.5Md BRL
Revenue growth (1y)
1213.10%
Hyper-growth
Revenue growth (3y)
30.51%
Solid
EPS growth (1y)
-19.60%
Declining
EPS CAGR (5y)
11.56%
Fair
EPS revisions (3 months)
17.36%
Sharply revised up
Valuation
6.6/10P/E 14.0x, forward P/E 9.7x, EV/EBITDA 21.0x, PEG 1.21. The multiple sits in the 48th percentile of its own 5-year history.
P/E (TTM)
14.0x
Cheap
Sector 30.1x|S&P 23.0x
Forward P/E
9.7x
Cheap
EV / EBITDA
21.0x
Expensive
Sector 15.1x|S&P 14.5x
PEG
1.21
Fair
Sector 0.75|S&P 0.86
Fair value (reverse DCF)
18.01 BRL
Undervalued
P/E vs its own 5-year history
among the 48% lowest valuations
In line with its history
Market cap
41.3Md BRL
Financial strength
10.0/10Cash covers 6440.3% of the debt, net debt/EBITDA -0.3x.
Net debt / EBITDA
-0.3x
Very solid
Gearing (net debt / equity)
-69.42%
Net cash
Cash
14.0Md BRL
Cash / market cap
33.78%
Very solid
Cash / total debt
6440.33%
Net cash
Net debt
-13.7Md BRL
Equity
19.8Md BRL
Closed daily candles, 2 years
Last close on September 23, 2026: 14.10 BRL
- MM2014.52
- MM5014.53
- MM20013.47
- RSI 1443.7
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+2.10%
200-day average slope, 3 months
+4.48%
50-day average slope, 1 month
+0.67%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
2.22 % per day
Volatility change
+6.05%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 1.43 (6) | 1.51 (5) | 52 290 (8) | 3 608 (5) | 4 293 (8) |
| 2027 | 1.69 (6) | 1.68 (5) | 59 557 (8) | 4 253 (6) | 4 997 (8) |
Amounts in millions of BRL, EPS in BRL per share. In brackets, the number of analysts. Consensus as of September 21, 2026.
Same sub-industry: 10 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PGNY | 7.5 | 7.8 | 2.0Md USD | 28.1x | 6.0 % | 5.3 % | 15.5 % | -3.1x | 9.0 % | 20.2 % | ||
| 2 | HQY | 7.3 | 6.9 | 7.5Md USD | 32.6x | 17.4 % | 7.6 % | 7.7 % | 1.4x | 6.5 % | -5.7 % | ||
| 3 | UNH | 7.3 | 6.5 | 333Md USD | 23.9x | 3.1 % | 0.4 % | 8.4 % | 1.9x | 7.1 % | 7.1 % | ||
| 4 | SAUD3 | 7.0 | 6.0 | 8.0Md USD | 14.0x | 10.6 % | 1213.1 % | 10.4 % | -0.3x | 1.7 % | 8.3 % | ||
| 5 | ELV | 6.7 | 5.9 | 86.4Md USD | 17.7x | 2.5 % | 1.4 % | 6.7 % | — | 7.3 % | 22.7 % | ||
| 6 | CNC | 6.0 | 5.1 | 30.7Md USD | Not meaningful (loss) | -2.5 % | 9.9 % | -12.2 % | 1.5x | 29.2 % | 89.2 % | ||
| 7 | HUM | 5.6 | 4.2 | 45.0Md USD | 35.5x | 0.9 % | 26.2 % | 4.1 % | -1.9x | 4.3 % | 47.6 % | ||
| 8 | CLOV | 4.8 | 3.8 | 2.4Md USD | Not meaningful (loss) | -0.7 % | 55.6 % | -5.1 % | 3.5x | 3.1 % | 38.3 % | ||
| 9 | MOH | 4.4 | 2.5 | 9.9Md USD | Not meaningful (loss) | -0.0 % | -4.8 % | -0.1 % | -20.7x | 2.7 % | 6.0 % |
